Prior antihistamine agent successfully impaired cutaneous adverse reactions to COVID‐19 vaccine

The coronavirus disease 2019 (COVID‐19) vaccine is positively changing the health crises of this pandemic and is currently essential to overcome the COVID‐19 pandemic. The vaccine shows high efficacy against the infection and impairs the severity of symptoms. However, this vaccination is associated with concerns, such as vaccine‐associated adverse reactions, which are currently highlighted issues for clinicians. We experienced two cases of mild cutaneous adverse reaction following COVID‐19 vaccine administration, which was successfully controlled by prior administration of the antihistamine agent fexofenadine 3 days before COVID‐19 vaccination for 7 days. The delayed cutaneous hypersensitivity reaction is commonly observed in clinical patients and medications are recognized as the representative causative agents. Although the vaccine is currently essential to overcome this difficult situation of the COVID‐19 pandemic, these vaccine‐associated adverse reactions have been currently highlighted issues for clinicians. Herein, we report a previously reported case of mild form cutaneous adverse reaction to COVID‐19 vaccine was successfully controlled by pre‐treatment with anti‐histamine drug administration.

IgA Vasculitis: Etiology, Treatment, Biomarkers and Epigenetic Changes.

IgA, previously called Henoch-Schönlein vasculitis, is an essential immune component that drives the host immune response to the external environment. As IgA has the unique characteristic of a flexible response to broad types of microorganisms, it sometimes causes an autoreactive response in the host human body. IgA vasculitis and related organ dysfunction are representative IgA-mediated autoimmune diseases; bacterial and viral infections often trigger IgA vasculitis. Recent drug developments and the presence of COVID-19 have revealed that these agents can also trigger IgA vasculitis. These findings provide a novel understanding of the pathogenesis of IgA vasculitis. In this review, we focus on the characteristics of IgA and symptoms of IgA vasculitis and other organ dysfunction. We also mention the therapeutic approach, biomarkers, novel triggers for IgA vasculitis, and epigenetic modifications in patients with IgA vasculitis.